Immunity Care and Research, LLC, Initiates Phase I Clinical Trial for Agouron Pharmaceuticals, Inc. Business Wire
click here to return to Business Wire main menu
DonateNow





Immunity Care and Research, LLC, Initiates Phase I Clinical Trial for Agouron Pharmaceuticals, Inc.

Business Wire - Wednesday May 26, 1999


PLANTATION, Fla.--(BW HealthWire)--May 26, 1999--Immunity Care and Research, LLC announced today it has begun a Phase I clinical trial with its investigational drug candidate, AG1549 a second generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection being developed by Agouron Pharmaceuticals, Inc.

Immunity Care and Research, LLC, an international site management organization (SMO) is conducting this Phase I trial which will evaluate the safety, tolerance, pharmacokinetics and antiviral activity in 30 HIV patients.

Dr. Jose Hernadez, Agouron's principle investigator for the study, commented, "This type of research study is critical for the development of new compounds for the treatment of HIV/AIDS due to the ever increasing numbers of patients in need of new therapies."

Immunity Care and Research, Inc. (ICR) is a international site management organization (SMO) which specializes in the conduct of Phase I-IV clinical trials in the areas of infectious diseases, principally HIV/AIDS and hepatitis. ICR manages clinical trials research in public health departments, community based medical clinics in the U.S. and has dedicated clinical research facilities located in San Juan, Puerto Rico and Santo Domingo, Dominican Republic.

Agouron Pharmaceuticals, Inc. is an integrated pharmaceutical company committed to the discovery, development, manufacturing, and marketing of innovative therapeutic products engineered to inactivate proteins that play key roles in cancer, AIDS, and other serious diseases.

Contact: Immunity Care and Research, LLC, Plantation Andrew Deme, 954/472-6778 or visit our Web site at: http://www.icrx.com or you may visit the Agouron Web Site at: http://www.agouron.com
990526
BW990509


Copyright © 1999 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .